Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass.
Spiekermann
B F
BF
Department of Anesthesiology, University of Virginia Health Sciences Center, Charlottesville 22908.
Lake
C L
CL
Rich
G F
GF
Humphries
J E
JE
D000368:Aged; D000721:Ancrod / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D002315:Cardiopulmonary Bypass; D005337:Fibrin / Q000502:physiology; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D013921:Thrombocytopenia / Q000139:chemically induced*; D013924:Thrombophlebitis / Q000139:chemically induced*; D013997:Time Factors; D014914:Whole Blood Coagulation Time
D005337:Fibrin; D006493:Heparin; D000721:Ancrod